Jump to content

2007 ASCO round up!


Recommended Posts

Among the data emerging at this year's American Society of Clinical Oncology meeting in Chicago were results showing that a combination treatment regimen of Celgene Corp.'s Revlimid (lenalidomide) and Millennium Pharmaceuticals' Velcade (bortezomib), along with dexamethasone, yielded a complete response rate of 35 percent and an overall response rate of 100 percent in newly diagnosed myeloma patients.

For Full article click here Its Kinda Long so............



Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.